Stocks Rise to Kick off Shortened Trading Week
U.S. stock futures rose early Tuesday to start out a shortened trading week, as investors kept an eye on Washington for developments on the global trade front. Futures for the Dow Jones Industrials advanced 67 points, or 0.2%, to 44,702Futures for the S&P 500 claimed 21.75 points or 0.4%, to 6,153.75.Futures for the tech-heavy NASDAQ sprang up 91.75 points, or 0.4%, to 22,288. Wall Street is coming off a winning week for the major averages. The Dow Jones Industrial Average gained roughly 0.6% last week, while the S&P 500 advanced 1.5%. The NASDAQ Composite rose 2.6%.Much of last week’s advance came Thursday after President Donald Trump’s plan for reciprocal tariffs on countries with levies on U.S. goods soothed investors who worried they would be more stringent.Stocks have been choppy to start the year but, even with ongoing concerns around trade and inflation, a look at the major averages show that they are not too far off their recent highs as investors scan for a catalyst for the next leg higher.The 30-stock Dow and the NASDAQ are about 1% off their recent records, while the S&P 500 is just 0.2% off its own milestone.Earnings season continues Tuesday. Occidental Petroleum and Arista Networks are among the companies set to report results.In Japan, the Nikkei 225 backtracked 0.8% Tuesday, while in Hong Kong, the Hang Seng zoomed 1.6%. Oil prices took on 52 cents to $71.26 U.S. a barrel. Gold prices $26.50 to $2,927.20 U.S. an ounce.
Recent Posts

Romanian Inflation Ends Tumultuous Year in Politics Close to 10%

UK Boosts Support For Offshore Wind in Bumper Auction

Ireland Is Trying to Get Back on the Data Center Bandwagon

Notice Concerning Change of Representative Executive Officer

Polish Recycler Bets Millions on Europe’s Critical Metals Push

Blistering Metals Rally Sends Silver, Tin and Copper to Records

Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities

TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics


